- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07951411
Evaluating the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Evaluate the Efficacy and Safety of SAL0167 Tablets at Different Doses in Participants With Hyperlipidemia.
This is a randomized, double-blind, placebo-controlled, multicenter phase II clinical trial. The purpose of this study is to evaluate the efficacy and safety of SAL0167, an oral PCSK9 inhibitor, in lowering low-density lipoprotein cholesterol (LDL-C) in participants with hyperlipidemia. Participants will be randomized 1:1:1:1 to receive low-dose SAL0167, medium-dose SAL0167, high-dose SAL0167, or placebo for a treatment period of 8 weeks.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The duration of the study for each participant is approximately 16 weeks, including a screening period of up to 2 weeks, a lead-in period of at least 4 weeks, a double-blind treatment period of 8 weeks, and a safety follow-up period of 2 weeks. We plan enrolled 240 participants with hyperlipidemia, both male and female. The participants were classified according to the ASCVD risk levels as per the "Chinese Guidelines for Lipid Management (2023)", and their LDL-C levels did not reach the treatment targets.
Qualified participants will enter the lead-in period. At the end of the lead-in period, the compliance will be re-evaluated. Participants with a compliance of 80% to 120% and meeting the criteria will be randomly assigned in a 1:1:1:1 ratio to the low-dose SAL0167, medium-dose SAL0167, high-dose SAL0167, or placebo group. The randomly assigned trial participants will then enter an 8-week double-blind treatment period. After the treatment is completed, a 2-week safety follow-up period will follow.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Jianping Li, M.D
- Número de teléfono: 13521531013
- Correo electrónico: 13521531013@163.com
Ubicaciones de estudio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana, 100034
- Peking University First Hospital
-
Contacto:
- Jianping Li, M.D
- Número de teléfono: 13521531013
- Correo electrónico: 13521531013@163.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Voluntarily participate in the trial and be able to understand and sign the Informed Consent Form (ICF).
- Sign the ICF when the age is ≥ 18 years old, regardless of gender.
- BMI should be within the range of 18 kg/m2 to 40 kg/m2, with men weighing ≥ 50.0 kg and women weighing ≥ 45.0 kg.
- According to the "Chinese Guidelines for Lipid Management (2023)", the ASCVD risk level should be classified and LDL-C should not meet the standard.
- Fasting LDL-C should be < 4.9 mmol/L.
- Fasting triglycerides (TG) should be ≤ 5.6 mmol/L.
- During the lead-in period, the medication compliance rate of the test drugs between 80% and 120%.
Exclusion Criteria:
- Have used drugs with weight loss effects or undergone surgeries that cause unstable weight within the past 2 months.
- Have been using systemic glucocorticoids continuously or repeatedly for more than 3 months.
- Have a disease that significantly affects lipid levels and is uncontrollable.
- Have hyperthyroidism or hypothyroidism that is uncontrollable.
- Have type 1 diabetes or poorly controlled type 2 diabetes.
- Participants had one of the following conditions a) Positive hepatitis B surface antigen (HBsAg) and/or positive hepatitis C antibody. b) Positive HIV antibody and/or syphilis spirochete antibody test results. c) eGFR < 45 mL/min/1.73m2. d) Creatine phosphokinase (CK) > 3×ULN.
- Poorly controlled hypertension.
- NYHA-defined grade Ⅲ-Ⅳheart failure, or have prolonged QTcF.
- Have poorly controlled severe arrhythmia within the past 3 months, such as recurrent and highly symptomatic ventricular tachycardia, rapid ventricular reactivity atrial fibrillation or supraventricular tachycardia, etc.
- Have myocardial infarction, unstable angina pectoris, percutaneous coronary intervention, coronary artery bypass grafting, severe deep vein thrombosis or pulmonary embolism or cerebrovascular accident within the past 3 months; or plan to undergo cardiac surgery or cardiac revascularization during the study period.
- Have had malignant tumors within the past 5 years.
- Have undergone any major organ transplantation, such as lung, liver, heart, bone marrow, kidney.
- Have participated in or are participating in other clinical studies and received drugs or devices within 5 half-lives before the screening and first administration of this study.
- Have undergone major surgery (non-ambulatory surgery) within the past 3 months or plan to undergo major surgery during the study period.
- Have undergone lipoprotein apheresis within the past 3 months or plan to undergo this treatment during the study period.
- Have a history of alcohol abuse within the past 6 months.
- Are pregnant (positive pregnancy test for women of childbearing age) or lactating.
- The participant and their spouse or partner have a pregnancy plan, or do not agree to adopt an acceptable at least one effective contraceptive method during the study period and after the last administration.
- Have an allergy to the active ingredient of SAL0167 or any excipient.
- Have severe cognitive dysfunction and cannot cooperate with medication or follow-up.
- The investigator considers the participant unsuitable for the clinical trial.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: test group 1
SAL0167 Dose 1 |
SAL0167 Dose 1 |
|
Experimental: test group 2
SAL0167 Dose 2 |
SAL0167 Dose 2 |
|
Experimental: test group 3
SAL0167 Dose 3 |
SAL0167 Dose 3 |
|
Comparador de placebos: Reference Group
Placebo |
placebo |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Periodo de tiempo: to Week 8
|
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 8 |
to Week 8
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants With LDL-C Value at Goal
Periodo de tiempo: at Week 8
|
Percentage of Participants With LDL-C Value at Goal at Week 8 |
at Week 8
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Jianping Li, M.D, Peking University First Hospital
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SAL0167A201
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .